Anti-CD19 x Anti-CD28 Bispecific Antibody (IgG-IgG) is designed to be generated by crosslinking two full length IgGs, anti-CD19 and anti-CD28 parental antibodies. A stable linkage is formed between the two antibodies. This BsAb can retarget T cells to tumor cells. It is designed for the research of B cell lymphoma; Follicular lymphoma; Leukemia therapy.
There are currently no customer reviews or questions for Anti-CD19 x Anti-CD28 Bispecific Antibody (IgG-IgG) (BSIG-040). Click the button below to contact us or submit your feedback about this product.
Welcome! For price inquiries, we will get back to you as soon as possible.
INQUIRYSERVICES
PRODUCTS
PLATFORMS